Karyopharm - oncology

Quote
anonymous said:
Yes, and the original Kyprolis folks know how this will likely play out. J and T will be next to leave, either on their own or get fired like P. They want ‘their’ people in those roles as it’s the only way ‘their’ way of doing things works. Mass exodus at the HOS level will ensue…which is what R and S want. As the RBD’s leave they will backfill them with Amgen people.

Wish I could say it was a good run…but it really wasn’t. At least at Onyx we made some money before having to work for the Amgen nut jobs…not so here. Waste of the last 2.5 years…
Click to expand...


Was having the same thought! Can’t believe I have to work with the Amgen idiots again…well at least for the short term. Agreed that this was a huge waste of time and a bad decision coming here, what’s even more aggravating is that many of us blindly stayed, while turning down far better opportunities…all those who left already look really smart.
 




RP will rearrange some deck chairs, strut around while deluding himself into believing that he’s always the smartest person in the room, shout down and belittle anyone who dares to challenge him and might make it obvious he doesn’t know what he’s talking about, and be sure to be long gone when the crap hits the fan.
 
























anonymous said:
A bunch of our best reps went to ADC, those that remain are Onynx crybabies.
Click to expand...

Simply not true. A bunch? What’s a bunch to you? Onyx crybabies? Why because they call BS when they see it and speak up versus being a scared wuss too afraid to speak up and call the out the nonsense? Keep stepping and fetching…the Onyx folks were loyal to P and now they too will leave. SC can bring in a bunch of supportive care reps and managers from Amgen…and we all the dismal failure Amgen reps are in actual therapeutic oncology…Blin, Kyprolis(once in Amgen hands wildly underperformed), T-Vec, Vectibix? Not a blockbuster amongst them. You have a commodity contracted supportive care drug hire Amgen reps all day they sell the contracts, they don’t sell clinically.
 








anonymous said:
Simply not true. A bunch? What’s a bunch to you? Onyx crybabies? Why because they call BS when they see it and speak up versus being a scared wuss too afraid to speak up and call the out the nonsense? Keep stepping and fetching…the Onyx folks were loyal to P and now they too will leave. SC can bring in a bunch of supportive care reps and managers from Amgen…and we all the dismal failure Amgen reps are in actual therapeutic oncology…Blin, Kyprolis(once in Amgen hands wildly underperformed), T-Vec, Vectibix? Not a blockbuster amongst them. You have a commodity contracted supportive care drug hire Amgen reps all day they sell the contracts, they don’t sell clinically.
Click to expand...

Does Paulson’s European wife make a difference?
 




anonymous said:
Based on KPTI sales you dont sell clinically either.
Click to expand...

Guessing you don’t understand hematology…this drug has limited use, a limited indication with a limited patient population, with data that is clinically undifferentiated. We are doing the best we can do with this dog drug. MK and S have an unrealistic view of ‘their’ drug and it’s potential, which is not the commercial team’s fault. Execution is not the issue and sure P and J became the scapegoats but in a year from now, under RP and SC’s ‘leadership’, when sales are flat it will be fun to see if we hold SC and RP accountable…
 




anonymous said:
Guessing you don’t understand hematology…this drug has limited use, a limited indication with a limited patient population, with data that is clinically undifferentiated. We are doing the best we can do with this dog drug. MK and S have an unrealistic view of ‘their’ drug and it’s potential, which is not the commercial team’s fault. Execution is not the issue and sure P and J became the scapegoats but in a year from now, under RP and SC’s ‘leadership’, when sales are flat it will be fun to see if we hold SC and RP accountable…
Click to expand...

RP is very good at blaming everyone else.
 




anonymous said:
Guessing you don’t understand hematology…this drug has limited use, a limited indication with a limited patient population, with data that is clinically undifferentiated. We are doing the best we can do with this dog drug. MK and S have an unrealistic view of ‘their’ drug and it’s potential, which is not the commercial team’s fault. Execution is not the issue and sure P and J became the scapegoats but in a year from now, under RP and SC’s ‘leadership’, when sales are flat it will be fun to see if we hold SC and RP accountable…
Click to expand...

I understood things well enough to leave. If you are such a star rep you would have done the same.
 












anonymous said:
Has wonder boy fixed everything yet?
Click to expand...

As unenthusiastic as we all are about the Amgen Invasion, no one can fix a dog drug and Seli is a dog. MOA only sells if it delivers above and beyond efficacy, which it does not, so all it is, is interesting science, that doesn’t really increase positive outcomes.
 




anonymous said:
As unenthusiastic as we all are about the Amgen Invasion, no one can fix a dog drug and Seli is a dog. MOA only sells if it delivers above and beyond efficacy, which it does not, so all it is, is interesting science, that doesn’t really increase positive outcomes.
Click to expand...

Agreed…bad product and now even worse senior leadership…who even thought that was possible…definitely time to get out as this is going to go from bad to worse very quickly.
 
















Top Bottom
Back
Quote